Table 2.
Comparison of IC50 values for concentration-effect curves of anti-malarial drugs against Plasmodium falciparum and Plasmodium vivax generated by different programs
| P. falciparum | P. vivax | ||||||
|---|---|---|---|---|---|---|---|
| Method | Geometric mean IC50 [nM] (95 % CI) | Median difference ICa50 [nM] (range) | Method | Geometric mean IC50 [nM] (95 % CI) | Median difference ICa50 [nM] (range) | ||
| Chloroquine (n = 31) | NONMEM | 91.40 (74.39–108.40) | Chloroquine (n = 29) | NONMEM | 151.9 (124.2–179.6) | ||
| GP | 81.43 (67.67–98.00) | 0.42 (−7.80 to 6.50) | GP | 137.8 (115.8–163.9) | 0.37 (−50.0-32.0) | ||
| HNL | 81.59 (67.26–98.97) | 0.42 (−5.50 to 13.0) | HNL | 136.7 (114.3–163.5) | 0.33 (−47.0 to 35.0) | ||
| ICE | 82.59 (68.45–99.65) | 1.50 (−5.00 to 11.0) | ICE | 137.4 (115.7–163.2) | 1.80 (−62.0 to 10.0) | ||
| IVART | 83.85 (69.20–101.6) | 0.93 (−12.0 to 40.0) | IVART | 135.2 (113.0–161.7) | 1.90 (−62.0 to 17.0) | ||
| WNL | 81.40 (67.62–98.00) | 0.51 (−5.40 to 5.10) | WNL | 136.4 (114.7–162.1) | 0.18 (−63.0 to 12.0) | ||
| Piperaquine (n = 31) | NONMEM | 25.65 (20.79–30.50) | Piperaquine (n = 28) | NONMEM | 26.03 (18.99–33.08) | ||
| GP | 21.77 (17.79–26.64) | 0.56 (−9.60 to 3.30) | GP | 20.46 (15.51–26.99) | −0.08 (−3.80 to 2.30) | ||
| HNL | 22.35 (18.30–27.30) | −0.22 (−5.10 to 13.0) | HNL | 21.26 (16.21–27.89) | 0.68 (−4.80 to 6.90) | ||
| ICE | 22.72 (18.44–27.99) | 0.44 (−3.00 to 4.90) | ICE | 20.99 (15.99–27.54) | 0.14 (−1.70 to 3.10) | ||
| IVART | 22.10 (17.88–27.32) | −0.02 (−11.0 to 4.90) | IVART | 21.34 (16.35–27.85) | 0.24 (−2.20 to 3.80) | ||
| WNL | 21.93 (17.92–26.85) | −0.28 (−9.20 to 3.30) | WNL | 20.64 (15.68–27.18) | −0.05 (−1.80 to 1.70) | ||
| Mefloquine (n = 31) | NONMEM | 13.49 (10.26–16.71) | Mefloquine (n = 29) | NONMEM | 21.67 (15.23–28.11) | ||
| GP | 10.99 (8.55–14.11) | 0.01 (−1.30 to 2.90) | GP | 16.53 (12.12–22.56) | 0.27 (−0.81 to 4.40) | ||
| HNL | 11.31 (8.85–14.45) | 0.24 (−0.89 to 3.80) | HNL | 16.61 (12.24–22.54) | 0.26 (−2.30 to 3.40) | ||
| ICE | 11.31 (8.84–14.46) | 0.38 (−0.15 to 2.80) | ICE | 16.82 (12.38–22.87) | 0.56 (−0.32 to 3.20) | ||
| IVART | 10.59 (8.14–13.76) | 0.03 (−5.10 to 3.10) | IVART | 16.61 (12.00–23.00) | 0.51 (−2.50 to 5.40) | ||
| WNL | 11.04 (8.59–14.17) | 0.03 (−0.82 to 2.30) | WNL | 16,341 (12.01–22.43) | 0.12 (−1.20 to 3.00) | ||
| Amodiaquine (n = 30) | NONMEM | 14.53 (12.18–16.88) | Amodiaquine (n = 28) | NONMEM | 24.97 (20.29–29.64) | ||
| GP | 13.40 (11.21–16.03) | −0.05 (−2.70 to 11.0) | GP | 22.03 (17.4–27.80) | 0.04 (−3.60 to 8.00) | ||
| HNL | 13.59 (11.42–16.18) | 0.46 (−2.80 to 2.60) | HNL | 22.31 (17.66–28.18) | 1.10 (−2.10 to 4.50) | ||
| ICE | 13.24 (11.16–15.71) | 0.04 (−1.10 to 0.87) | ICE | 21.74 (17.34–27.25) | 0.07 (−1.80 to 0.81) | ||
| IVART | 13.24 (11.16–15.71) | 0.04 (−1.10 to 0.87) | IVART | 21.88 (17.31–27.10) | −0.03 (−1.80 to 0.81) | ||
| WNL | 13.38 (11.22–15.96) | −0.04 (−1.30 to 11.0) | WNL | 21.88 (17.36–27.57) | −0.02 (−2.20 to 4.30) | ||
| Artesunate (n = 31) | NONMEM | 5.43 (3.23–7.63) | Artesunate (n = 28) | NONMEM | 4.12 (2.38 to 5.85) | ||
| GP | 3.59 (2.48–5.19) | 0.01 (−0.14 to 1.10) | GP | 2.47 (1.63–3.75) | 0.01 (−0.64 to 0.82) | ||
| HNL | 3.57 (2.52–5.07) | −0.01 (−2.60 to 11.0) | HNL | 2.55 (1.69–3.85) | 0.06 (−0.73 to 2.60) | ||
| ICE | 3.51 (2.48–4.67) | 0.05 (−0.14 to 0.99) | ICE | 2.50 (1.65–3.79) | 0.04 (−0.30 to 0.79) | ||
| IVART | 3.54 (2.54–4.94) | 0.07 (−2.90 to 0.84) | IVART | 2.45 (1.61–3.72) | 0.01 (−0.63 to 0.43) | ||
| WNL | 3.61 (2.49–5.23) | 0.01 (−0.40 to 10.0) | WNL | 2.48 (1.63–3.76) | 0.01 (−0.41 to 1.00) | ||
aMedian difference (range) for each method compared with NONMEM (values in italics) used as the reference method for comparison